Skip to main content

Chronic Constipation

17
Pipeline Programs
15
Companies
24
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
8
0
5
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%
+ 25 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
2
TegaserodPhase 41 trial
TegaserodPhase 41 trial
TegaserodPhase 31 trial
Active Trials
NCT00141089Completed1,026Est. Feb 2005
NCT00348634Terminated60Est. Apr 2007
NCT00149877Completed250Est. Feb 2006
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
1
TegaserodPhase 4
Norgine
NorgineAustria - Vienna
4 programs
1
1
2
Polyethylene glycol 3350 Na bicarbonate NaCl KClPhase 31 trial
Polyethylene glycol 3350 Na bicarbonate NaCl KClPhase 31 trial
Polyethylene glycol 3350 NA bicarbonate NaCl KClPhase 21 trial
PEG 3350 plus electrolytesPhase 11 trial
Active Trials
NCT00868985Completed114
NCT00404040Completed60Est. Jul 2002
NCT00403897Completed81Est. Jan 2003
+1 more trials
Astellas
AstellasChina - Shenyang
2 programs
1
1
linaclotidePhase 3Peptide1 trial
ASP0456Phase 21 trial
Active Trials
NCT02425722Completed383Est. Oct 2015
NCT02809105Completed186Est. Nov 2017
EA Pharma
EA PharmaJapan - Tokyo
1 program
1
AJG555Phase 31 trial
Active Trials
NCT02961556Completed39Est. Aug 2017
Kissei Pharmaceutical
Kissei PharmaceuticalJapan - Matsumoto City
4 programs
4
KWA-0711Phase 21 trial
KWA-0711Phase 21 trial
KWA-0711Phase 21 trial
KWA-0711Phase 21 trial
Active Trials
NCT02281630Completed388
NCT01937663Completed
NCT01938196Completed
+1 more trials
Alfasigma
AlfasigmaItaly - Bologna
1 program
1
TD-5108Phase 21 trial
Active Trials
NCT00391820Completed360Est. May 2007
Theravance Biopharma
1 program
1
TD-5108Phase 2
Ironwood Pharmaceuticals
5 programs
linaclotide acetatePHASE_21 trial
LinaclotidePHASE_3Peptide1 trial
Linaclotide 290 microgramsPHASE_31 trial
Linaclotide 290 microgramsPHASE_31 trial
Matching PlaceboPHASE_31 trial
Active Trials
NCT00402337Completed310Est. Feb 2008
NCT00765999Completed1,559Est. Jan 2012
NCT01642914Completed487Est. Aug 2013
+2 more trials
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Perineal Self-AcupressureN/A1 trial
Active Trials
NCT01867944Completed100
Eisai
EisaiChina - Liaoning
1 program
AJG555PHASE_3
Ipsen
IpsenChina - Tianjin
1 program
PEG 4000PHASE_31 trial
Active Trials
NCT00255372Completed88Est. May 2008
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Elobixibat 10mgPHASE_41 trial
Active Trials
NCT05165199UnknownEst. Mar 2023
Takeda
TakedaTOKYO, Japan
1 program
prucalopridePHASE_41 trial
Active Trials
NCT01707667Completed13Est. Nov 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City TherapeuticsElobixibat 10mg
Takedaprucalopride
SandozTegaserod
SandozTegaserod
EA PharmaAJG555
Astellaslinaclotide
Ironwood PharmaceuticalsLinaclotide 290 micrograms
Ironwood PharmaceuticalsLinaclotide
Ironwood PharmaceuticalsLinaclotide 290 micrograms
Ironwood PharmaceuticalsMatching Placebo
IpsenPEG 4000
SandozTegaserod
NorginePolyethylene glycol 3350 Na bicarbonate NaCl KCl
NorginePolyethylene glycol 3350 Na bicarbonate NaCl KCl
AstellasASP0456

Showing 15 of 22 trials with date data

Clinical Trials (24)

Total enrollment: 6,877 patients across 24 trials

NCT05165199City TherapeuticsElobixibat 10mg

Elobixibat for Chronic Constipation Without Defecation Desire

Start: Mar 2022Est. completion: Mar 2023
Phase 4Unknown
NCT01707667Takedaprucalopride

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

Start: Feb 2013Est. completion: Nov 201313 patients
Phase 4Completed
NCT00348634SandozTegaserod

Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients

Start: Jul 2006Est. completion: Apr 200760 patients
Phase 4Terminated
NCT00149877SandozTegaserod

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

Start: Apr 2004Est. completion: Feb 2006250 patients
Phase 4Completed
NCT02961556EA PharmaAJG555

General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation

Start: Nov 2016Est. completion: Aug 201739 patients
Phase 3Completed
NCT02809105Astellaslinaclotide

A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation

Start: Jun 2016Est. completion: Nov 2017186 patients
Phase 3Completed
NCT01642914Ironwood PharmaceuticalsLinaclotide 290 micrograms

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Start: Aug 2012Est. completion: Aug 2013487 patients
Phase 3Completed
NCT00765999Ironwood PharmaceuticalsLinaclotide

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Start: Oct 2008Est. completion: Jan 20121,559 patients
Phase 3Completed
NCT00765882Ironwood PharmaceuticalsLinaclotide 290 micrograms

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Start: Sep 2008Est. completion: Aug 2009633 patients
Phase 3Completed
NCT00730015Ironwood PharmaceuticalsMatching Placebo

Trial of Linaclotide in Patients With Chronic Constipation

Start: Aug 2008Est. completion: Oct 2009643 patients
Phase 3Completed
NCT00255372IpsenPEG 4000

To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

Start: Apr 2005Est. completion: May 200888 patients
Phase 3Completed
NCT00141089SandozTegaserod

Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.

Start: Mar 2004Est. completion: Feb 20051,026 patients
Phase 3Completed
NCT00403819NorginePolyethylene glycol 3350 Na bicarbonate NaCl KCl

Study to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children

Start: Apr 2002Est. completion: Apr 200360 patients
Phase 3Completed
NCT00403897NorginePolyethylene glycol 3350 Na bicarbonate NaCl KCl

An Open Single Centre Study To Assess Treatment of Chronic Constipation in Children

Start: Aug 2001Est. completion: Jan 200381 patients
Phase 3Completed
NCT01937663Kissei PharmaceuticalKWA-0711

A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation

Phase 2Completed
NCT01938196Kissei PharmaceuticalKWA-0711

A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation

Phase 2Completed
NCT02425722AstellasASP0456

A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation

Start: Apr 2015Est. completion: Oct 2015383 patients
Phase 2Completed
NCT02343978Kissei PharmaceuticalKWA-0711

Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)

Start: Dec 201437 patients
Phase 2Completed
NCT02281630Kissei PharmaceuticalKWA-0711

Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)

Start: Oct 2014388 patients
Phase 2Completed
NCT00402337Ironwood Pharmaceuticalslinaclotide acetate

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Start: Nov 2006Est. completion: Feb 2008310 patients
Phase 2Completed
NCT00391820AlfasigmaTD-5108

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Start: Oct 2006Est. completion: May 2007360 patients
Phase 2Completed
NCT00404040NorginePolyethylene glycol 3350 NA bicarbonate NaCl KCl

Movicol in Childhood Constipation (ProMotion Study)

Start: Oct 2000Est. completion: Jul 200260 patients
Phase 2Completed
NCT00868985NorginePEG 3350 plus electrolytes

Effects of Oral PEG 3350 on Electrolyte Balance

Start: Jan 2008114 patients
Phase 1Completed
NCT01867944Angeles TherapeuticsPerineal Self-Acupressure

Perineal Self-Acupressure

Start: Jun 2013100 patients
N/ACompleted

Related Jobs

Senior Manager, FP&A

Ironwood PharmaceuticalsIronwood Pharmaceuticals
Boston, Massachusetts, United States
1mo ago
$102K - $203K/yr

Head of Drug Product Development

Ironwood PharmaceuticalsIronwood Pharmaceuticals
Boston, Massachusetts, United States
1mo ago
$246K - $287K/yr

Senior Director, Investor Relations and Corporate Communications

Ironwood PharmaceuticalsIronwood Pharmaceuticals
Boston, Massachusetts, United States
1mo ago
$246K - $287K/yr

Clinical Operations Lead, Development Operations

Ironwood PharmaceuticalsIronwood Pharmaceuticals
Basel, Switzerland
2mo ago

Director, Global Regulatory Affairs (GRA) - CMC

Ironwood PharmaceuticalsIronwood Pharmaceuticals
Boston, Massachusetts, United States
2mo ago
$162K - $277K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.